028300

HLB is a South Korean diversified manufacturer operating in healthcare, biotechnology, and marine equipment. The company is organized into three main business segments: healthcare, biotechnology, and shipbuilding. In healthcare, HLB manufactures and sells in-vitro diagnostic medical devices, such as specimen collection kits and blood glucose monitors, along with pharmaceutical quasi-drugs like alcohol swabs and disinfectants, and cosmetic products. Its biotechnology segment focuses on the development of targeted cancer therapies, including the oral tyrosine kinase inhibitor Rivoceranib for hepatocellular carcinoma and the licensed-in drug lirafugatinib for cholangiocarcinoma. The shipbuilding segment designs and builds special-purpose vessels, including patrol boats and leisure craft, and manufactures lifeboats, davits, and GRP/GRE pipes for ballast and scrubber systems. HLB serves domestic and international pharmaceutical companies, diagnostic device manufacturers, government agencies, coast guards, navies, and shipyards. The company was founded in 1975, originally as a lifeboat manufacturer, and has since expanded into global pharmaceutical and biotechnology development.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage hlbbio.co.kr
Sector Healthcare IR page hlbbio.co.kr/ir/financial/disclosure
Tags
in-vitro diagnostics, targeted cancer therapy, hepatocellular carcinoma, cholangiocarcinoma, special-purpose vessels, lifeboats, grp pipes, pharmaceutical quasi-drugs, biotechnology, marine equipment, Rivoceranib, lirafugatinib, Elevar Therapeutics, Immunomic Therapeutics, Verismo Therapeutics, HLB ENG, HLB Healthcare, HLB Bio
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -44.3%
ROI -52.7%
ROIC -18.7%
Profit margin -262.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 84.173B 68.126B 42.901B 179.708B 69.826B 56.177B 38.421B 36.186B 23.007B 30.139B 38.461B 37.186B 31.452B
Net profit -220.501B -91.98B -189.079B -76.668B -98.125B -80.093B -44.386B 25.343B -16.53B -13.215B 12.64B -2.931B -8.545B
Free cash flow -109.535B -134.281B -117.501B -73.551B -56.952B -57.486B -50.376B -21.189B -20.784B -11.783B -2.007B -5.635B -4.853B

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 2.93B 3.24B 6.53B 6.58B 11.7B 34B 15.1B 7.23B 8.92B 9.52B
↳ YoY growth -39.0% +10.7% +101.4% +0.8% +78.4% +189.7% -55.5% -52.3% +23.4% +6.7%
↳ 5y CAGR +2.9% -3.8% +19.6% +63.3% +36.1% +2.0% +6.3% -4.1%
Borrowings, current (KRW) 7.33B 31.5B 11B 12.1B 44B 21.2B 115B 28.7B 99.4B 207B
Borrowings, non-current (KRW) 6.06B 4.32B 31.6B 74.5B 614M 47.4B 320M 17.9B 44.4B 58.2B
Lease liabilities (KRW) — — — — — — 14.3B 16B 16.3B 19.7B
Cash and deposits (KRW) 9.37B 7.35B 30.2B 40.9B 221B 99.8B 196B 109B 93B 41B
Intangible assets (KRW) 131B 127B 134B 134B 264B 340B 345B 269B 312B 334B
Right-of-use assets (KRW) — — — — — 9.47B 12.6B 11.3B 11.1B 14.7B
Net debt (borrowings + leases - cash) (KRW) -3.31B 28.5B 12.3B 45.8B -176B -31.2B -80.2B -62.3B 67B 244B
Cash flow detail
Operating cash flow (KRW) -10.2B -19.1B -20.7B -48.7B -56.5B -54.8B -61.8B -112B -114B -92.6B
Purchases of property, plant and equipment (KRW) -1.63B -1.7B -517M -1.72B -972M -2.19B -11.7B -5.87B -20B -16.9B
Purchases of intangible assets (KRW) -789M -364M -78.5M -163M -74B -3.95B -893M -1.19B -7.1B -586M
Dividends paid (cash effect) (KRW) — — 0.00 0.00 -83.6M — — — — —
Share buybacks (cash effect) (KRW) — — 0.00 0.00 -3.81B 0.00 0.00 -4.08B 0.00 0.00
Interest paid (cash effect) (KRW) -242M -228M -441M -2.47B -326M -217M -350M -1.29B -2.1B -3.27B
Income taxes paid (cash effect) (KRW) 77.6M 3.28M -16.8M -68.9M -120M 7.8B -5.7B -5.8B 197M 5.93B
Free cash flow (OCF - PPE - intangibles) (KRW) -12.6B -21.1B -21.3B -50.5B -131B -60.9B -74.4B -119B -141B -110B
Income detail
Total comprehensive income (KRW) -22.9B -23.9B 18.7B -51.8B -104B -86.3B -77.2B -200B -65.2B -244B
Comprehensive income to owners (KRW) -13.2B -17.8B 29B -38.8B -95.3B -75.4B -60.6B -184B -54.1B -228B
Reported Nov 14, 2017 Mar 30, 2018 Mar 22, 2021 Mar 22, 2021 Mar 22, 2021 Mar 21, 2024 Mar 21, 2025 Mar 21, 2025 Mar 21, 2025 Mar 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

주요사항보고서(회사합병결정) Bull 1 Bear 3 M&A
신주인수권행사가액의조정 Bull 0 Bear 0 Routine
분기보고서 (2026.09) Bull 0 Bear 0 Results

Prompts

HLB (ticker 028300), listed in South Korea.

ETFs Holding HLB

ETF Weight in ETF Shares Market value As of
NTSE 0.03% 570 $ 19.131K Jun 30, 2026
DFSE 0.01% 3,367 $ 74.403K Nov 12, 2026
DFAE 0.01% 28,293 $ 625.213K Nov 12, 2026
DEXC 0.01% 629 $ 13.9K Nov 12, 2026
DFEM 0.00% 11,120 $ 245.727K Nov 12, 2026
DFAX 0.00% 6,248 $ 138.067K Nov 12, 2026
AVEM 0.00% 1 $ 20.79 Nov 16, 2026